140 related articles for article (PubMed ID: 12871505)
1. Recombinant human microplasmin: production and potential therapeutic properties.
Nagai N; Demarsin E; Van Hoef B; Wouters S; Cingolani D; Laroche Y; Collen D
J Thromb Haemost; 2003 Feb; 1(2):307-13. PubMed ID: 12871505
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
Dommke C; Turschner O; Stassen JM; Van de Werf F; Lijnen HR; Verhamme P
J Thromb Thrombolysis; 2010 Jul; 30(1):46-54. PubMed ID: 19834783
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
Suzuki Y; Nagai N; Collen D
J Thromb Haemost; 2004 Sep; 2(9):1617-21. PubMed ID: 15333039
[TBL] [Abstract][Full Text] [Related]
4. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Lapchak PA; Araujo DM; Pakola S; Song D; Wei J; Zivin JA
Stroke; 2002 Sep; 33(9):2279-84. PubMed ID: 12215599
[TBL] [Abstract][Full Text] [Related]
5. Effects of microplasmin on recovery in a rat embolic stroke model.
Rasmussen RS; Overgaard K; Pakola S; Boysen G
Neurol Res; 2008 Feb; 30(1):75-81. PubMed ID: 17588313
[TBL] [Abstract][Full Text] [Related]
6. Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Nagai N; De Mol M; Van Hoef B; Verstreken M; Collen D
Blood; 2001 May; 97(10):3086-92. PubMed ID: 11342434
[TBL] [Abstract][Full Text] [Related]
7. [Effect of recombinant microplasmin on acute cerebral infarction in rats].
Fu JY; Ren JP; Zou LB; Bian GX; Li RF; Lü QJ
Yao Xue Xue Bao; 2007 Dec; 42(12):1266-70. PubMed ID: 18338639
[TBL] [Abstract][Full Text] [Related]
8. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
9. A novel human microplasmin fold: new perspective to thrombosis treatment.
Joison AN; Gallo FS
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):236-9. PubMed ID: 21245749
[TBL] [Abstract][Full Text] [Related]
10. Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.
Suzuki Y; Chen F; Ni Y; Marchal G; Collen D; Nagai N
Stroke; 2004 Oct; 35(10):2402-6. PubMed ID: 15322296
[TBL] [Abstract][Full Text] [Related]
11. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Nagai N; Suzuki Y; Van Hoef B; Lijnen HR; Collen D
J Thromb Haemost; 2005 Jul; 3(7):1379-84. PubMed ID: 15978095
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
13. [Microplasmin instead of a scalpel].
Heidingsfeld A; Koob V; Kräuter N; Kupka J; Rastetter A; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2009; 38(4):299-300. PubMed ID: 19572347
[No Abstract] [Full Text] [Related]
14. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
15. Thrombolysis with plasmin: implications for stroke treatment.
Marder VJ; Jahan R; Gruber T; Goyal A; Arora V
Stroke; 2010 Oct; 41(10 Suppl):S45-9. PubMed ID: 20876504
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
Kornowski R; Chernine A; Hasdai D; Ovadia Z; Battler A
Eur Heart J; 1995 Feb; 16(2):177-83. PubMed ID: 7744088
[TBL] [Abstract][Full Text] [Related]
17. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.
Wikström K; Mattsson C; Pohl G
Thromb Res; 1993 May; 70(3):217-24. PubMed ID: 8392227
[TBL] [Abstract][Full Text] [Related]
18. Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.
Chen F; Suzuki Y; Nagai N; Sun X; Wang H; Yu J; Marchal G; Ni Y
Radiology; 2007 Aug; 244(2):429-38. PubMed ID: 17581889
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
20. Timing of Symptomatic Infarct Swelling Following Intravenous Thrombolysis in Acute Middle Cerebral Artery Infarction: A Case-Control Study.
Lin TC; Lee JD; Lin YH; Yuan RY; Weng HH; Huang YC; Lee M; Wu CY; Hsu HL; Hsu CY; Lee TH; Liu SJ; Chang YJ; Chang CH; Peng TI; Liou CW; Chang KC; Pan YT; Huang YC
Clin Appl Thromb Hemost; 2017 Oct; 23(7):814-820. PubMed ID: 27443695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
